Colorectal cancer vaccine - Shanghai Haixin Biotechnology

Drug Profile

Colorectal cancer vaccine - Shanghai Haixin Biotechnology

Alternative Names: APDC - Shanghai Haixin Biotechnology; autologous tumor lysates pulsed human dendritic cells vaccine - Shanghai Haixin Biotechnology

Latest Information Update: 06 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Haixin Biotechnology
  • Developer Second Military Medical University; Shanghai Haixin Biotechnology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 17 Feb 2005 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top